Article
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
PloS one - 1 Jan 2019
Watanabe Fumiaki, Suzuki Koichi, Tamaki Sawako, Abe Iku, Endo Yuhei, Takayama Yuji, Ishikawa Hideki, Kakizawa Nao, Saito Masaaki, Futsuhara Kazushige, Noda Hiroshi, Konishi Fumio, Rikiyama Toshiki
Abstract excerpt
BACKGROUND: Liquid biopsies enable the detection of circulating tumor DNA (ctDNA). However, the clinical significance of KRAS-mutated ctDNA for pancreatic cancer has been inconsistent with respect to its prognostic and predictive potential. METHODS AND FINDINGS: A total of 422 blood samples were collected from 78 patients undergoing treatments for localized and metastatic pancreatic ductal adenocarcinoma. KRAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
